Article Figures & Data
Figures
- FIGURE 1.
Typical immediate (0–30 min) anterior (A) and posterior (B) view, and 22-h anterior (C) and posterior (D) view images after 123I-IAZA intravenous administration to volunteer. Images were obtained from volunteer 3 (27-y-old man) after injection of 207.2 MBq (5.62 mCi) 123I-IAZA into right arm.
- FIGURE 2.
Plots of mean dose-normalized disposition of total radioactivity and 123I-IAZA (experimental data) and radioactive metabolites (derived data) in human volunteers after 123I-IAZA administration. Data are plotted as percentage injected dose per milliliter of blood and are not decay corrected. ○ = total radioactivity; • = 123I-IAZA; ▾ = radioactive metabolites. (Reprinted with permission of (12).)
Tables
Organ Total dose mGy/MBq rad/mCi Adrenals 8.5E-03 ± 8.3E-04 3.2E-02 ± 3.1E-03 Brain 5.5E-03 ± 5.3E-04 2.0E-02 ± 2.0E-03 Breasts 4.7E-03 ± 4.7E-04 1.7E-02 ± 1.7E-03 GB wall 1.2E-02 ± 1.7E-03 4.6E-02 ± 6.1E-03 LLI wall 5.6E-02 ± 1.2E-02 1.7E-01 ± 7.9E-02 Small intestine 2.4E-02 ± 5.1E-03 7.2E-02 ± 3.3E-02 Stomach 8.7E-03 ± 9.5E-04 3.2E-02 ± 3.5E-03 ULI wall 5.0E-02 ± 1.2E-02 1.5E-01 ± 7.0E-02 Heart wall 7.2E-03 ± 7.4E-04 2.7E-02 ± 2.7E-03 Kidneys 1.9E-02 ± 9.2E-04 7.0E-02 ± 3.5E-03 Liver 1.4E-02 ± 3.0E-03 5.2E-02 ± 1.1E-02 Lung 6.7E-03 ± 7.3E-04 2.5E-02 ± 2.7E-03 Muscle 7.1E-03 ± 5.8E-04 2.6E-02 ± 2.2E-03 Ovaries 1.8E-02 ± 3.1E-03 6.7E-02 ± 1.1E-02 Pancreas 9.0E-03 ± 8.7E-04 3.3E-02 ± 3.3E-03 Red marrow 7.2E-03 ± 6.3E-04 2.7E-02 ± 2.4E-03 Bone surfaces 1.2E-02 ± 1.1E-03 4.5E-02 ± 3.9E-03 Skin 4.5E-03 ± 3.8E-04 1.7E-02 ± 1.4E-03 Spleen 7.7E-03 ± 6.6E-04 2.8E-02 ± 2.5E-03 Testes 7.0E-03 ± 1.9E-04 2.6E-02 ± 6.9E-04 Thymus 6.2E-03 ± 6.2E-04 2.3E-02 ± 2.3E-03 Thyroid 4.4E-02 ± 1.4E-02 1.4E-01 ± 7.9E-02 UB wall 6.3E-02 ± 8.7E-03 2.0E-01 ± 8.9E-02 Uterus 1.6E-02 ± 1.4E-03 5.8E-02 ± 5.5E-03 TB 8.0E-03 ± 7.1E-04 3.0E-02 ± 2.6E-03 Effective dose equivalent 2.1E-02 ± 2.8E-03* 7.9E-02 ± 1.0E-02† Effective dose 2.2E-02 ± 2.4E-03* 8.0E-02 ± 9.1E-03† - TABLE 2
Dosimetry Estimates Comparison Between 123I-IAZA and Several Other Radiopharmaceuticals for Adults Using 2-Hour Bladder Void Time
Generic name ULI LLI Thyroid Urinary bladder wall Total body Reference 123I-IAZA 5.0E-02 5.6E-02 4.4E-02 6.3E-02 8.0E-03 This study 123I-Tropane 4.3E-02 4.6E-02 5.7E-02 9.7E-02 N/A 17 EDE = 3.2E-02 131I-Iodobenguane sulfate N/A N/A 9.2E-02 8.0E-01 6.2E-02 19 99mTc-Bicisate 1.6E-02 1.3E-02 3.5E-03 3.0E-02 2.4E-03 20 99mTc-Sestamibi 4.9E-02 3.5E-02 6.2E-03 1.8E-02 4.6E-03 21 ULI = upper large intestinal wall; LLI = lower large intestinal wall; N/A = not provided in product monograph; EDE = effective dose equivalent (mSv/MBq).
Values are in mGy/MBq.
Organ Volunteer no. Mean SD 1 2 3 4 5 6 Liver 8.00 6.82 6.85 7.12 9.13 6.19 7.35 1.05 Kidney 7.86 5.45 7.39 6.32 8.84 9.29 7.53 1.47 Thyroid 8.29 6.60 7.11 6.31 7.55 5.25* 7.17 0.79 RB 7.02 6.21 6.09 6.60 7.41 6.12 6.57 0.54 ↵* Thyroid ROI absent.
Data are in hours and are based on WB scintigraphic image analysis at 5 time points within 24-h period after 123I-IAZA administration.
- TABLE 4
Comparison of Gamma Camera and Serum-Based Pharmacokinetic Methods Used to Estimate MRT and RT and Percentage of Total Radioactivity Eliminated in Urine
Volunteer no. Gamma camera Pharmacokinetic* PK/gamma camera RTTB (h) Urine (%) MRTTB (h) Urine (%) RTTB/MRTTB Urine 1 7.44 88.9 7.25 95.3 0.97 1.07 2 7.01 92.0 7.28 85.1 1.04 0.92 3 6.88 92.8 5.95 64.4† 0.86 0.069 4 6.85 87.5 6.52 93.5 0.95 1.07 5 7.38 88.7 7.67 91.2 1.04 1.03 6 7.60 88.0 6.40 97.0 0.84 1.10
